Bronger Ingham discontinues the high blood pressure drug Catapres

In 2020, the company decided to permanently discontinue the product after it recalled several batches of the prestigious antihypowder cola after the results of an under-standard test were released.
week, the FDA's website announced that all three doses of the Grigg Ingham hypertension drug catapres, also known as cola hydrochloride, were in short supply.
, but with a large number of generics on the market, this is not a serious problem for patients.
has decided to quietly phase out the decades-old high blood pressure product, according to foreign media.
0.1 mg, 0.2 mg and 0.3 mg tablets are already in short supply on the market as a result of a voluntary Level 2 recall of seven batches of Catapres in October 2020, a spokesman for Bronger Ingeham said by email.
, we have made the FDA aware of the company's decision to stop production of Catapres in the future," the spokesman said.
there are generic alternatives, and if patients have any difficulty getting Catapres, they should contact their healthcare provider to discuss alternative treatment options.
" Cola was patented in 1961 and began treating hypertension in 1966, and has since been approved for treatment of attention deficit hyperdymodyne disorder, drug withdrawal (alcohol, opioids or smoking), menopausal redness, diarrhea, spasms, and certain pain conditions.
to treat high blood pressure by stimulating alpha2 ligands in the brain, thereby reducing the resistance of outer blood vessels and lowering blood pressure.
the drug usually takes effect within an hour and the effect on blood pressure lasts eight hours.
2017, it is the 79th most commonly used prescription drug in the United States, with more than 10 million prescriptions a year.
October 2020, Bronger Ingham recalled Catapres, which included four batches of 0.1 mg tablets, two batches of 0.2 mg tablets and one batch of 0.3 mg tablets, after additional spikes in drug solubility test results.
at the time that the test results did not pose a risk to patients and advised patients taking the drug to continue taking the drug as directed by their doctor.
spokesman for
Grigg Ingham made it clear that the supply of other Colody products continued unanswered under the FDA's list of drug shortages, and that the recall did not include any of the company's other drugs.
pharmaceutical companies are currently producing coke-based generics, including generic giant Teva.
this isn't the first time the drugmaker that makes Coke has run into problems.
as early as 2017, the FDA sent Frontida BioPharm a warning letter about a Philadelphia plant it had acquired from Sun Pharma, an Indian pharmaceutical giant.
fda warning letter said sun Pharma deliberately marketed 27 batches of cola hydrochloride tablets at different concentrations, despite evidence that cola hydrochloride was "likely to be contaminated."
source: 1. Wikipedia 2.Boehringer Ingelheim quietly culls decade-old hypertension medd after October recall